Wednesday, 26 August 2026European Markets

MOREFIELD GROUP Stock Bearish By 9% So Far On Wednesday

Loading stream...

(VIANEWS) - Shares of MOREFIELD GROUP (AEX-Index: MORE.AS) dropped 9.14% to €0.32 at 14:12 EST on Wednesday, following the last session's downward trend. AEX-Index is jumping 1.48% to €767.01, after three sequential sessions in a row of gains. This seems, up to now, an all-around positive trend trading session today.

MOREFIELD GROUP's last close was €0.29, 24.68% under its 52-week high of €0.39.

About MOREFIELD GROUP

Morefield Group N.V. does not have significant operations. Previously, the company was involved in the external professionals hiring activities. The company was formerly known as HeadFirst Source Group N.V. and changed its name to Morefield Group N.V. in January 2019. Morefield Group N.V. is based in Willemstad, Curaçao.

Earnings Per Share

As for profitability, MOREFIELD GROUP has a trailing twelve months EPS of €0.09.

PE Ratio

MOREFIELD GROUP has a trailing twelve months price to earnings ratio of 3.53. Meaning, the purchaser of the share is investing €3.53 for every euro of annual earnings.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MOREFIELD GROUP's stock is considered to be overbought (>=80).

Moving Average

MOREFIELD GROUP's worth is higher than its 50-day moving average of €0.29 and higher than its 200-day moving average of €0.31.

More news about MOREFIELD GROUP (MORE.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com